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Background: The main goal of this randomized controlled single-blinded pilot study was to study whether,
independent of weight loss, a Palaeolithic-type diet alters characteristics of the metabolic syndrome. Next we
searched for outcome variables that might become favourably influenced by a Paleolithic-type diet and may
provide new insights in the pathophysiological mechanisms underlying the metabolic syndrome. In addition, more
information on feasibility and designing an innovative dietary research program on the basis of a Palaeolithic-type
diet was obtained.
Methods: Thirty-four subjects, with at least two characteristics of the metabolic syndrome, were randomized to a
two weeks Palaeolithic-type diet (n = 18) or an isoenergetic healthy reference diet, based on the guidelines of the
Dutch Health Council (n = 14). Thirty-two subjects completed the study. Measures were taken to keep bodyweight
stable. As primary outcomes oral glucose tolerance and characteristics of the metabolic syndrome (abdominal
circumference, blood pressure, glucose, lipids) were measured. Secondary outcomes were intestinal permeability,
inflammation and salivary cortisol. Data were collected at baseline and after the intervention.
Results: Subjects were 53.5 (SD9.7) year old men (n = 9) and women (n = 25) with mean BMI of 31.8 (SD5.7) kg/m2.
The Palaeolithic-type diet resulted in lower systolic blood pressure (−9.1 mmHg; P = 0.015), diastolic blood pressure
(−5.2 mmHg; P = 0.038), total cholesterol (−0.52 mmol/l; P = 0.037), triglycerides (−0.89 mmol/l; P = 0.001) and higher
HDL-cholesterol (+0.15 mmol/l; P = 0.013), compared to reference. The number of characteristics of the metabolic
syndrome decreased with 1.07 (P = 0.010) upon the Palaeolithic-type diet, compared to reference. Despite efforts
to keep bodyweight stable, it decreased in the Palaeolithic group compared to reference (−1.32 kg; P = 0.012).
However, favourable effects remained after post-hoc adjustments for this unintended weight loss. No changes
were observed for intestinal permeability, inflammation and salivary cortisol.
Conclusions: We conclude that consuming a Palaeolithic-type diet for two weeks improved several cardiovascular
risk factors compared to a healthy reference diet in subjects with the metabolic syndrome.
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The metabolic syndrome (MetS) is a clustering of symp-
toms that usually derive from a combination of over
nutrition and a sedentary lifestyle [1]. Because of the
worldwide rapidly increasing prevalence of the MetS
and its high risk of progression to type 2 diabetes melli-
tus (DM2) [2,3] and cardiovascular disease (CVD)
[4], preventive measures are urgently needed. Lifestyle-
induced insulin resistance and chronic systemic low
grade inflammation may be central in the pathophysio-
logical cascade towards the MetS [5]. Although dietary
management and lifestyle modifications are the corner-
stones in the treatment and prevention of metabolic
disorders, specific guidelines for the MetS have not yet
been established. There is considerable evidence that
the dietary composition may favourably affect the com-
ponents of the MetS. Various authors have pointed at
the discordance between our contemporary diet and
that of our Palaeolithic ancestors, which has shaped our
core metabolism and physiology during the past 2.5 mil-
lion years. Evolution predicts that such diets may also
be optimal for prevention and treatment of metabolic
disorders associated with obesity, DM2, CVD and insu-
lin resistance [6-13]. Previously reported studies with
Palaeolithic-type diets were conducted with healthy
subjects [14,15] or patients with CVD [16], DM2 [17] or
obesity [18,19]. There are no studies on the effects of a
Palaeolithic-type diet targeting subjects with the MetS.
The conducted trials showed that Palaeolithic-type diets
may effectively lower bodyweight, waist circumference
and BP [14], lower serum lipids [18] and improve insu-
lin response in healthy volunteers within less than three
weeks [15]. A major limitation of these three studies
was the lack of a reference group. Controlled studies
in patients with ischaemic heart disease [16], DM2
[17] or obese postmenopausal women [19], without cor-
rection for possible weight loss, showed a larger im-
provement of various CVD risk factors after consuming
a Palaeolithic-type diet. Consequently, it is uncertain
whether any of the positive health effects in these
studies could also be on account of the accompanying
weight loss as opposed to the composition of the
Palaeolithic-type diet per se.
The main goal of the current pilot study was to com-
pare metabolic effects of a Palaeolithic-type diet with
those of a healthy reference diet, independent of weight
loss, in subjects with the MetS. Next we studied out-
come variables that might become favourably influenced
by a Palaeolithic-type diet, and thereby provide new in-
sights into the pathophysiological mechanisms under-
lying the MetS and CVD. The third goal was to obtain
more information on feasibility and how to design and
develop an innovative dietary research program on the
basis of a Palaeolithic-type diet.Methods
Study design
This was a stratified (men/women), randomized con-
trolled single-blinded pilot study conducted in the
Netherlands. Subjects with characteristics of the MetS
were randomized to a two weeks dietary intervention
with either a Palaeolithic-type diet or a healthy refer-
ence diet. Emphasis was put on the prevention of weight
loss during the intervention. The study took place at the
Louis Bolk Institute in Driebergen, the Netherlands, in
October-December 2011. Laboratory measurements were
performed in the Diakonessenhuis, Zeist, the Netherlands.
Subjects
Eligible subjects were 18–70 years old adults who gave
written consent and had at least two of the following
characteristics of the MetS [20]: 1. Central obesity (waist
circumference ≥102 cm for men and ≥88 cm for women)
2. Elevated triglycerides ≥1.7 mmol/l 3. Reduced HDL-
cholesterol <1.0 mmol/l for men and <1.3 mmol/l for
women) 4. Raised BP ≥130/85 mmHg or BP medication
and 5. Elevated fasting plasma glucose ≥5.6 mmol/l. Ex-
clusion criteria were DM2, CVD, smoking, systolic BP >
180 mmHg, hypoglycaemic medication, pregnancy and
severe internal or psychiatric disease. The study was ap-
proved by the Medical Ethics Committee Wageningen
University and conducted according to the principles
expressed in the Declaration of Helsinki.
Study settings
Subjects were recruited in September-October 2011
through advertisements in local newspapers and posters in
primary health care units. After telephone contact a first
selection was made and subjects were enrolled during a
screening visit by the research physician. It was not known
to the subjects whether any of the diets would be superior
to the other (single-blinded). After randomization, sub-
jects of the different diet groups could not communicate
with each other. Before and directly after the intervention
period subjects visited the Diakonessenhuis in Zeist for
physical measurements, OGTT and blood sampling. All
meals were delivered at their homes free of charge by a
catering service.
Dietary interventions
The Palaeolithic-type diet intervention was based on an-
thropological Palaeolithic research [21,22] with a con-
cern for feasibility in modern times. It was based on lean
meat, fish, fruit, leafy and cruciferous vegetables, root
vegetables, eggs and nuts. Dairy products, cereal grains,
legumes, refined fats, extra salt and sugar were not part
of it. The reference diet was based on the guidelines for
a healthy diet of the Dutch Health Council [23-31]. Both
diets were designed as seven consecutive daily menus
Table 1 Nutrient and caloric composition of the dietary
intervention programs
Nutrient Palaeolithica Referencea RDAb
En% En% En%
Energy (kJ) 8 703 8 690 8 374
Protein (en%),(g) 24 123 17 91 10-25
vegetable protein (g) 22 39 none
animal protein (g) 101 52 none
Carbohydrate (en%),(g) 32 164 50 261 40-70
mono/disaccharides (g) 132 109 none
Fat (en%),(g) 41 94 29 68 20-40
saturated (en%),(g) 10 24 9 21 <10
monounsaturated (g) 44 26.5 none
polyunsaturated (g) 19 14.6 none
linoleic acid (g) 14 11 4-6
EPA (mg) 640 210 EPA + DHA:
450
DHA (mg) 950 360 EPA + DHA:
450
Fibre (en%),(g) 3 34 2.7 28 30-40
Sodium (mg) 2 194 2 121 <2 400
Potassium (mg) 5 859 3 932 4 700
Calcium (mg) 575 1 181 1 000
Magnesium (mg) 494 415 250-300
Iron (mg) 16.4 12.6 8-15
Selenium (mg) 110 50 50-150
Zinc (mg) 13.6 12.0 9-10
Phosphorus (mg) 1 661 1 729 700-1 400
Copper (mg) 2.0 1.4 1.5-3.5
Iodine (mcg) 138 219 150
Vitamin A (mcg) 1 317 705 700-900
Vitamin B1 (mg) 1.5 1.0 1.1
Vitamin B2 (mg) 1.4 1.7 1.1-1.5
Vitamin B3 (mg) 35 19 13-17
Vitamin B6 (mg) 2.8 1.7 1.5
Vitamin B12 (mcg) 11.5 4.2 2.8
Vitamin C (mg) 264 142 70
Vitamin D (mcg) 4.3 3.7 3.3
Folate (mcg) 398 331 300
Abbreviation: En%, energy percentage.
aCalculations were based on the Dutch NeVo table [30].
bRecommended Dietary Allowances were based on recommendation of the
Dutch Health Council [22-29].
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the basis of an isoenergetic intake of 8 700 kJ. Although
coffee and tea were not part of a Palaeolithic-type diet,
subjects were allowed to drink, in view of possible with-
drawal symptoms, up to two cups of coffee or black tea
per day. Any medication was continued at the same dos-
ages. Additional detailed information on the two diets is
summarized in Table 1.
Prevention of weight loss
Before the intervention all subjects recorded their usual
diet using a food record diary. This diary was used by
the dietician to adjust diets to individual energy demand
by providing (additional) program-related snacks to
prevent weight loss within the intervention period.
Bodyweight was measured every second day. A daily
bodyweight fluctuation of 2 kg was considered accept-
able. Next to keeping bodyweight stable, importance was
emphasized of keeping their usual exercise level during
the intervention.
Compliance
To ensure compliance to the intervention, all subjects
were requested to keep records of the food consumed.
In addition, each subject was encouraged every other
day by telephonic contact with their personal coach to
complete all meals and to discuss their progress, body-
weight fluctuation, possible physical and psychological
discomforts or adverse events. A total of six personal
coaches (each coaching 5–6 subjects) were involved dur-
ing the study, who could be reached by the subjects for
any questions concerning catering, daily recording or
measurements.
Outcomes
Primary endpoints were glucose tolerance measured by
the oral glucose tolerance test (OGTT) [32] and the
characteristics of the MetS (waist circumference, sys-
tolic/diastolic BP, lipids, fasting glucose). Additional ana-
lyses comprised intestinal permeability, inflammation
parameters (hsCRP, TNFα) and a stress parameter (saliv-
ary cortisol). Tolerability was measured by analysing the
adverse events reported during the study and by per-
forming blood tests for haematological indices and liver
and kidney functions.
Measurements
Systolic and diastolic BP, from which the mean values
were calculated, were measured twice after at least
10 min of sitting using an automated BP measuring de-
vice (OMRON M6 Comfort, OMRON Healthcare Co.
Ltd.). Bodyweight was measured using a digital Seca 803
scale. For the OGTT subjects ingested a solution con-
taining a 75 g glucose load. Plasma glucose and insulinconcentrations were measured at 0 (baseline), 30, 60
and 120 min after ingestion. AUCs for glucose and insu-
lin were calculated using the trapezoidal method. In
addition HOMAIR and the ratio between triglycerides
and HDL-cholesterol were determined as measures of
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intestinal permeability, which was measured using the
differential sugar absorption test (DSAT). After an over-
night fast, the subjects ingested a test solution contain-
ing 5 g lactulose, 2 g mannitol and 5 g D-xylose in
100 ml water. All urine portions passed in the subse-
quent five hours were collected in a plastic container
containing 0.5 ml 20% chlorhexidine as a preservative.
Results were expressed as the urinary lactulose:mannitol
ratio. Saliva was collected by Salivette® devices for as-
sessment of the diurnal cortisol slope. Subjects had to
chew on the cotton swab for 30–60 seconds. Sampling
was performed at wake time, 30–40 minutes after wak-
ing (peak time), 17.00 h and bedtime [33]. A flattening
slope of the diurnal cortisol curve is related to low-
grade inflammation, insulin resistance and the MetS43 subjects were asse
34 underwent r
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1 choose to join an o
18 were assigned to the 
Palaeolithic-type diet
None were lost to follow-up
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Figure 1 Flow diagram of the progress through enrolment, interventi[34-36]. At the end of the intervention, an evaluation
form on feasibility and motivational aspects was filled
out by all subjects.
Statistical methods
For this pilot design a sample size of 15 subjects per
group was estimated to be sufficient, because in previous
studies with Palaeolithic-type diets [15,21] the same
number of subjects showed positive changes in BP,
glucose tolerance, lipids and inflammation parameters
within two weeks. To allow for an estimated 20% drop
out, the total number of subjects was set at 36. Subjects
were stratified into two groups according to gender and
subsequently randomized using separate randomization
lists as generated by the Random Allocation Software
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ated the random allocation sequence and assigned
subjects to interventions. Descriptive statistics were cal-
culated with regard to demographical and categorical
data and mean scores and SDs of the numerical variables
using SPSS (version 17.0). Evaluation occurred according
to intention-to-treat. Mixed models were used to analyse
between groups. This model included intervention, gen-
der, intervention by gender, baseline BMI and the base-
line value of the specific outcome variable as fixed
effects, the intercept and subjects identification number
as random effects. Pair wise comparisons between the
two diets were made using the adjusted data. For these
differences 95% confidence intervals were calculated.
Two-way paired t-tests were used to analyse within-
subject changes per group according to per-protocol.
Results
The courses of inclusion and exclusion are shown in
Figure 1. A total of 34 subjects were randomized: 18
were allocated to the Palaeolithic group and 16 to the
reference group. Two subjects (2/16; 12.5%) dropped out
from the reference group for personal reasons. There were
only a few at random missing cortisol data, attributable to
some subjects who forgot to take a saliva sample.
Baseline data
Tables 2, 3 and 4 show the baseline demographic and
clinical characteristics of all subjects. Baseline data dif-
fered between both groups for BMI and number of
characteristics of the MetS. No differences were found for
coffee, tea and alcohol consumption, or the amount of
exercise and stress factors between the intervention groups.









Characteristics of the MetS (n), range 0-5 3.7
(1) Abdominal circumference ♂ ≥102 cm, ♀ ≥88 cm (%) 94.4
(2) Triglycerides ≥1.7 mmol/l (%) 38.9
(3) HDL-cholesterol ♂ <1.0 mmol/l , ♀ <1.3 mmol/l (%) 66.7
(4) BP ≥130/85 mmHg or BP medication (%) 83.3
(5) Glucose fasting ≥5.6 mmol/l (%) 77.8
*P values between the two intervention groups at baseline.Exception was the diurnal slope of cortisol showing a
skewed distribution.
Outcomes and estimation
Study subjects were 9 men and 25 women with an average
age of 53.5 (SD9.7) years, a mean BMI of 31.8 (SD5.7) and
an average number of 3.2 (SD1.3) characteristics of the
MetS. Compared to reference, the Palaeolithic group, had
lower mean systolic BP (−9.1 mmHg; P= 0.015), diastolic
BP (−5.2 mmHg; P= 0.038), total cholesterol (−0.52 mmol/l;
P= 0.037) and triglycerides (−0.89 mmol/l; P= 0.001) and a
higher mean HDL-cholesterol (+0.15 mmol/l; P= 0.013).
For detailed results see Tables 3 and 4. The number of char-
acteristics of the MetS decreased upon the Palaeolithic-type
diet (−1.07 characteristics; P = 0.010) compared to refer-
ence, resulting in less subjects with the actual MetS ac-
cording to the definition of the MetS [20] after the
intervention. There was a tendency for a larger decrease
of AUC insulin in the Palaeolithic group (−1 918 mU/l x
min versus +362 mU/l x min in the reference group;
P = 0.051) using two-tailed unpaired t-tests, however this
difference did not remain when adjusted for baseline BMI.
In both groups change was observed in waist circumfer-
ence (Palaeolithic: −3.1 cm; reference: −3.3 cm), fasting glu-
cose (Palaeolithic: −0.9 mmol/l; reference: −0.35 mmol/l)
and the ratio between urinary sodium and potassium
(Palaeolithic: −1.1; reference: −0.57), however no differ-
ences were seen between both groups. Fasting plasma
insulin (−2.7 mU/l) and HOMAIR (−0.9) only decreased
in the Palaeolithic group (Table 5). The ratio between
total cholesterol and HDL-cholesterol (−1.16 mol/mol;
P = 0.003) and the ratio between triglycerides and HDL-
cholesterol (−0.91 mol/mol; P = 0.0001) were lowered in
the Palaeolithic group compared to reference. Amongthic (n 18) Reference (n 16) P*
% SD Mean or % SD
75.0 0.86










Table 3 Summary results for each intervention group
Variable Palaeolithic (n 18) Reference (n 16) Pa Differenceb Pc
Mean SD Mean SD
Anthropometric
Bodyweight (kg) −1.3 (−2.3; −0.3) 0.01
Baseline 98.0 18.2 86.0 14.2 0.04
2 weeks 95.3 17.5 84.3 12.5
BMI (kg/m2) −0.5 (−0.9; −0.1) 0.01
Baseline 33.7 5.9 29.8 4.9 0.05
2 weeks 32.8 5.8 29.7 5.2
Abdominal circumference (cm) −0.4 (−2.4; 1.6) 0.69
Baseline 114.7 11.5 107.7 9.4 0.06
2 weeks 111.6 12.3 104.7 8.7
Systolic BP (mmHg) −9.1 (−16.2; −1.9) 0.02
Baseline 131 15 134 15 0.48
2 weeks 122 10 129 14 ·
Diastolic BP (mmHg) −5.2 (−10.0; −0.3) 0.04
Baseline 87 9 86 13 0.75
2 weeks 79 6 83 9 ·
Characteristics of the MetS (n), −1.1 (−1.9; −0.3) 0.01
range 0-5 Baseline 3.7 1.1 2.7 1.3 0.02
2 weeks 2.7 1.0 2.9 1.2
Glucose tolerance and insulin sensitivity
Glucose fasting (mmol/l) −0.1 (−0.5; 0.3) 0.68
Baseline 6.1 0.8 5.8 0.7 0.34
2 weeks 5.7 0.8 5.5 0.8
Insulin fasting (mU/l) −2 · 0 (−5.0; 1.1) 0.20
Baseline 11.9 5.5 10.2 6.5 0.40
2 weeks 9.2 4.9 9.5 5.3
HOMAIR
d −0.5 (−1.4; 0.4) 0.28
Baseline 3.3 1.7 2.7 1.8 0.32
2 weeks 2.4 1.6 2.4 1.3
AUC glucose (mmol/l x min) −27.7 (−156.6; 101.1) 0.66
Baseline 263 208 249 162 0.83
2 weeks 245 199 262 216
AUC insulin (mU/l x min) −1 342 · (−415; 3 099) 0.13
Baseline 8 791 6 200 6 270 3 619 0.16
2 weeks 6 873 2 692 6 955 3 365
TG:HDL-C (mol/mol) −0.9 (−1.3; −0.5) 0.00
Baseline 1.7 1.6 0.9 0.6 0.07
2 weeks 0.9 0.7 1.1 0.7
Lipids
TC (mmol/l) −0.5 (−1.0; −0.0) 0.04
Baseline 5.7 1.0 6.1 1.4 0.33
2 weeks 5.0 0.9 6.0 1.2
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Table 3 Summary results for each intervention group (Continued)
HDL-C (mmol/l) 0.2 (0.0; 0.3) 0.01
Baseline 1.3 0.4 1.6 0.4 0.06
2 weeks 1.3 0.4 1.4 0.4
LDL-C (mmol/l) −0.1 (−0.5; 0.3) 0.56
Baseline 3.5 0.7 3.9 1.4 0.27
2 weeks 3.2 0.8 3.9 1.1
TG (mmol/l) −0.9 (−1.3; −0.5) 0.00
Baseline 1.9 1.4 1.3 0.6 0.10
2 weeks 1.0 0.6 1.4 0.6
TC:HDL-C (mol/mol) −1.2 (−1.9; −0.4) 0.00
Baseline 4.6 1.5 3.5 2.1 0.11
2 weeks 4.0 1.3 4.5 1.5
Inflammation
hsCRP (mg/l) 0.1 (−2.2; 2.3) 0.96
Baseline 4.4 3.4 2.3 3.1 0.07
2 weeks 4.6 3.1 3.0 4.5
TNFα (pg/ml) −0.6 (−1.7; 0.6) 0.32
Baseline 3.9 1.8 4.3 3.0 0.65
2 weeks 4.0 1.6 4.3 3.1
Intestinal permeability
Lactulose:mannitol (mol/mol), in 5 h urine portion −0.007 (−0.023; 0.008) 0.35
Baseline 0.029 0.017 0.024 0.021 0.66
2 weeks 0.024 0.013 0.033 0.025
Stress parameter
Diurnal cortisol slope, wakeup-bedtime −0.08 (−0.36; 0.20) 0.54
Baseline −0.41 −0.30;-0.72e −0.38 −0.30;-0.70e 0.43
2 weeks −0.40 −0.22;-0.54e −0.57 −0.28;-0.62e
Abbreviations: TG triglycerides, HDL-C HDL-cholesterol, TC total cholesterol, LDL-C LDL-cholesterol.
Mean values and standard deviations, intention-to-treat.
aP values between the two intervention groups at baseline.
bDifference = Palaeolithic-type diet – reference diet. Values are 95% CI.
cP values between the two intervention groups after the intervention.
dFor HOMAIR the following equation was used: HOMAIR = (fasting insulin mmol/l x fasting glucose mU/l)/22.4.
eData are median (25st;75st percentile).
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γ-glutamyltransferase showed a decline in favour of the
Palaeolithic group. Urine analysis showed lower values
of magnesium and calcium in the Palaeolithic group
compared to reference. Other secondary outcome pa-
rameters showed no changes.
In line with the protocol, we took efforts to keep body-
weight stable. For nine subjects extra diet-related snacks
were necessary due to over 2 kg weight loss, without be-
ing hungry (seven in the Palaeolithic group = 38% versus
two in the reference group = 14%). Hunger was reported
once by three subjects in the Palaeolithic group at the
start of the intervention. According to food diaries and
coach reports, all subjects were able to complete theirdietary programs. At the end of the intervention body-
weight was nevertheless decreased in the Palaeolithic
group compared to reference (−1.32 kg; P = 0.012). After
adding this (unintended) weight loss as a separate fixed
effect in a post-hoc analysis we found that favourable
effects remained for systolic BP, HDL-cholesterol, tri-
glycerides, the ratio between triglycerides and HDL-
cholesterol, the ratio between total cholesterol and
HDL-cholesterol and the number of characteristics of
the MetS (Table 6).
Adverse events
One subject in the reference group reported a moderate ad-
verse event (nausea and diarrhoea) during the intervention
Table 4 Summary results for each intervention group – tolerability
Variable Palaeolithic (n 18) Reference (n 16) Pa Differenceb Pc
Mean SD Mean SD
Haematology
Hb (g/l) −1.6 (−6.4;3.2) 0.59
Baseline 145.0 11.3 141.8 8.1 0.44
2 weeks 145.0 11.3 143.4 9.7
Ht (l/l) 0.00 (−0.01;0.01) 0.93
Baseline 0.43 0.03 0.42 0.03 0.40
2 weeks 0.44 0.03 0.42 0.03
RBC (x10E12/l) −0.0 (−0.2;0.1) 0.58
Baseline 4.8 0.3 4.8 0.3 0.28
2 weeks 4.8 0.3 4.7 0.4
WBC (x10E9/l) −1.0 (−1.7;-0.2) 0.02
Baseline 7.2 1.9 7.1 1.7 0.88
2 weeks 6.3 1.2 7.0 1.8
Platelets (x10E9/l) −15.5 (−35.7;4.7) 0.13
Baseline 253.6 44.4 255.1 70.5 094
2 weeks 240.2 51.5 262.5 72.8
Liver and kidney function
ASAT (U/l) 0.9 (−3.1;4.9) 0.63
Baseline 27.6 7.0 26.3 6.8 0.57
2 weeks 30.6 6.8 25.3 6.6
ALAT (U/l) 1.9 (−5.5;9.2) 0.61
Baseline 35.1 16.8 25.9 11.9 0.08
2 weeks 38.2 17.7 25.1 10.2
GGT (U/l) −9.5 (−17.7;-1.3) 0.03
Baseline 27.3 11.1 38.9 39.3 0.24
2 weeks 21.9 8.1 37.6 40.1
AP (U/l) −4.0 (−9.4;1.5) 0.15
Baseline 79.3 22.1 70.0 13.3 0.15
2 weeks 74.1 21.3 70.1 11.5
Creatinine (μmol/l) −3.1 (−9.8;3.6) 0.36
Baseline 71.2 11.4 76.1 13.0 0.25
2 weeks 75.6 13.8 79.0 14.6
Urea (mmol/l) −0.0 (−0.8;0.8) 0.92
Baseline 4.9 1.3 5.1 1.2 0.58
2 weeks 5.7 1.6 6.0 1.3
Other laboratory parameters
Urine
Sodium (mmol/h) −0.5 (−1.7;0.8) 0.46
Baseline 6.3 0.2 6.7 2.9
2 weeks 3.8 2.7 3.4 1.0
Potassium (mmol/h) 0.1 (−1.1;1.2) 0.91
Baseline 3.5 1.3 4.0 1.6
2 weeks 3.8 1.5 3.4 1.3
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Table 4 Summary results for each intervention group – tolerability (Continued)
Magnesium (mmol/h) −0.04 (−0.07;-0.01) 0.03
Baseline 0.14 0.06 0.14 0.06
2 weeks 0.13 0.08 0.13 0.06
Calcium (mmol/h) −0.08 (−0.12;-0.04) 0.00
Baseline 0.13 0.13 0.19 0.20
2 weeks 0.08 0.05 0.16 0.10
Sodium:potassium (mmol/mol) −0.20 (−0.62;0.22) 0.34
Baseline 2.12 1.16 1.78 0.67 0.31
2 weeks 1.00 0.47 1.15 0.55
Serum
Homocysteine (μmol/l) 1.05 (−0.44;2.55) 0.16
Baseline 11.7 3.9 12.6 3.0 0.31
2 weeks 12.9 4.3 12.8 3.1
Abbreviations: Ht Haematocrit, RBC Red blood cell count, WBC White blood cell count, ASAT Aspartate aminotransferase, ALAT Alanine amino transferase,
GGT γ-Glutamyltransferase, AP Alkaline phosphatase.
Mean values and standard deviations, intention-to-treat.
aP values between the two intervention groups at baseline.
bDifference = Palaeolithic-type diet – reference diet (with 95% CI).
cP values between the two intervention groups after the intervention.
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lysis concerning haematology and liver and kidney function
showed no changes in relation to adverse events (Table 4).
Discussion
This is the first controlled study on the influence of a
Palaeolithic-type diet in subjects with characteristics of
the MetS. Over a two week period we found favourable
changes in most characteristics of the MetS: a lowering
of BP, a change in lipid spectrum and a tendency to
higher insulin sensitivity. Despite efforts to keep body-
weight stable, more weight loss was observed in the
Palaeolithic group, which is an important outcome of
our study. Nevertheless, favourable effects remained
after adding weight loss as a separate fixed effect in a
post-hoc analysis. No changes were found in specific in-
flammation parameters, intestinal permeability and the
diurnal cortisol slope, possibly explained by the short
duration of the dietary intervention or its constant body-
weight design. Indicators for new insights in the patho-
physiological mechanisms underlying the MetS and
CVD could possibly be found in the lowering effect on
white blood cell count and lower levels of urinary cal-
cium and magnesium. The generalizability of this study
might be high, because of the broad inclusion criteria,
men and women with diverse combinations and charac-
teristics of the MetS.
Interpretation
Our results are in line with results from earlier research
in related target groups. We found a lowering of systolicand diastolic BP, where in uncontrolled studies with
healthy volunteers [14,15] as well as in controlled studies
with diabetic patients [17] lowering of BP has also been
reported. Contrarily, BP lowering was not observed in
controlled studies concerning patients with ischaemic
disease [16] and obese postmenopausal women [19].
With respect to lipids, we found positive changes in total
cholesterol, triglycerides and HDL-cholesterol in favour
of the Palaeolithic group. Previous research also reported
positive changes in lipid profile in healthy subjects, dia-
betic patients or obese women [15,17-19]. In our study,
the ratio between total cholesterol and HDL-cholesterol,
which is an important risk factor for CVD employed
in clinical practice, was also lowered in the Palaeolithic
group compared to reference. In addition, the ratio be-
tween triglycerides and HDL-cholesterol, a proxy for in-
sulin resistance, was lowered in the Palaeolithic group
compared to reference. Regarding glucose tolerance we
did not find significant changes in our study. There was,
however, a tendency for a larger decrease of AUC insulin
and HOMAIR in the Palaeolithic group. In contrast to
our results, glucose tolerance improved within 10–17
days in healthy subjects after a Palaeolithic diet in an
uncontrolled study [15], as well as in a controlled study
of longer duration (3 months) in patients with ischemic
heart disease [16]. In our study we found for both groups
a decrease in abdominal circumference of approx. 3 cm,
but not as a specific effect of the Palaeolithic-type diet.
Earlier findings in 3 months [16,17] and 6 months [19]
controlled studies did report change in abdominal
circumference in favour of the Palaeolithic-type diet,
Table 5 Differences between baseline and after intervention for both groups
Variable Paired Differences
All (n 34) Palaeolithic (n 18) Reference (n 14)
Mean SD P* Mean SD P* Mean SD P*
Anthropometric
Abdominal circumference (cm) −3.2 2.2 0.00 −3.1 2.0 0.00 −3.3 2.4 0.00
Systolic BP (mmHg) −6.6 9.8 0.00 −8.5 12.0 0.01 −4.2 5.6 0.02
Diastolic BP (mmHg) −6.0 7.5 0.00 −8.0 8.3 0.0 −3.5 5.6 0.03
Glucose tolerance and insulin sensitivity
Glucose fasting (mmol/l) −0.4 0.5 0.00 −0.4 0.5 0.01 −0.4 0.4 0.00
Insulin fasting (mU/l) −2.1 4.3 0.01 −2.7 5.0 0.03 −1.4 3.2 0.14
HOMAIR −0.7 1.3 0.00 −0.9 1.5 0.03 −0.5 0.9 0.06
AUC glucose (mmol/l x min) −6 141 0.81 −18 170 0.66 9 98 0.73
AUC insulin (mU/l x min) −921 3 565 0.15 −1 918 4 361 0.08 362 1 515 0.39
TG:HDL-C (mol/mol) −0.4 1.0 0.04 −0.8 1.2 0.01 0.2 0.3 0.08
Lipids
TC (mmol/l) −0.6 0.7 0.000 −07 0.7 0.00 −0.4 0.5 0.02
HDL-C (mmol/l) −0.1 0.2 0.001 −0.0 0.1 0.38 −0.2 0.1 0.00
LDL-C (mmol/l) −0.2 0.5 0.01 −0.3 0.5 0.02 −0.2 0.5 0.18
TG (mmol/l) −0.5 1.0 0.01 −0.9 1.1 0.00 0.1 0.4 0.63
TC:HDL-C (mol/mol) 0.1 1.2 0.72 −0.5 0.7 0.01 0.9 1.3 0.03
Inflammation
hsCRP (mg/l) 0.3 2.5 0.54 0.2 2.8 0.79 0.4 2.1 0.49
TNFα (pg/ml) 0.2 1.3 0.45 0.1 1.6 0.87 0.3 0.7 0.13
Intestinal permeability
Lactulose:mannitol (mmol/mol) 0.003 0.020 0.3 −0.002 0.020 0.65 0.009 0.012 0.11
Other laboratory parameters
Urine
Sodium:potassium (mmol/mol) −0.88 0.93 0.00 −1.11 0.97 0.00 −0.57 0.82 0.02
Serum
Homocysteine (μmol/l) 0.8 1.6 0.01 1.2 1.3 0.00 0.3 1.9 0.60
Abbreviations: TG triglycerides, HDL-C HDL-cholesterol, TC total cholesterol, LDL-C LDL-cholesterol.
Mean values and standard deviations, per-protocol.
*P values for the difference between baseline and after intervention, computed by two-tailed paired t-test, not adjusted.
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obese postmenopausal women [19]. Also other low-
carbohydrate, high-protein or Mediterranean diets have
demonstrated to be effective in improving various
markers of cardiovascular risk in diabetic patients [37].
Unique for our study was the attempt to find these
favourable effects independently from the factor of
weight loss. Another notable observation was that char-
acteristics of the MetS can be reduced within a short
period in people with cardiovascular risk.
A frequently expressed critique on Palaeolithic-type diets is
related to their low calcium content. In our study there was
indeed a 50% lower calcium intake compared to the reference
diet (Table 1). However, due to higher dietary magnesium
intake compared to reference and compensation by lowerurinary calcium and magnesium excretion, calcium homeosta-
sis was unlikely to have become compromised.
Course of study and feasibility
Home catering with frequent coaching was a satisfactory
method to monitor the intake and whereabouts of the sub-
jects. Subjects remained motivated and were coached to
consume the prescribed food. Problems could be solved
adequately resulting in few drop-outs and missing data.
Nevertheless, we experienced that delivering fresh foods in
time across a wide region of the Netherlands was a logis-
tical challenge. For follow-up studies, attention to catering
aspects is of utmost importance. The experienced difficul-
ties in maintaining bodyweight could be part of the positive
effects of a Palaeolithic-type diet. Jönsson et al. [38,39]
Table 6 Post-hoc analysis: differences without and with weight loss added to the model
Variable Differencea Pb Adjusted differencec
weight loss added to the model
Pb
Anthropometric
Abdominal circumference (cm) −0.4 (−2.4;1.6) 0.69 −0.9 (−3.2;1.5) 0.56
Systolic BP (mmHg) −9.1 (−16.2;-1.9) 0.02 −13.0 (−25.4;-0.6) 0.04
Diastolic BP (mmHg) −5.2 (−10.0;-0.3) 0.04 −4.9 (−10.7;0.9) 0.09
Characteristics of the MetS (n) −1.1 (−1.9;-0.3) 0.01 −1.0 (−1.8;-0.1) 0.03
Glucose tolerance and insulin sensitivity
Glucose fasting (mmol/l) −0.1 (−0.5;0.3) 0.68 −0.0 (−0.5;0.5) 0.91
Insulin fasting (mU/l) −2.0 (−5.0;1.1) 0.20 −1.4 (−5.1;2.3) 0.44
HOMAIR −0.5 (−1.4;0.4) 0.28 −0.5 (−1.6;0.7) 0.41
AUC glucose (mmol/l x min) −28 (−157;101) 0.66 −107 (−247; 33) 0.13
AUC insulin (mU/l x min) −1 342 (−415; 3 099) 0.13 −484 (−2 503; 1 535) 0.63
TG:HDL-C (mol/mol) −0.9 (−1.3;-0.5) 0.00 −0.7 (−1.1;-0.3) 0.00
Lipids
TC (mmol/l) −0.5 (−1.0;-0.0) 0.04 −0.3 (−0.8;0.3) 0.35
HDL-C (mmol/l) 0.2 (0.0;0.3) 0.01 0.15 (0.01;0.29) 0.04
LDL-C (mmol/l) −0.1 (−0.5;0.3) 0.56 −0.1 (−0.5;0.4) 0.75
TG (mmol/l) −0.9 (−1.3;-0.5) 0.00 −0.7 (−1.0;-0.3) 0.00
TC:HDL-C (mol/mol) −1.2 (−1.9;-0.4) 0.00 −1.1 (−2.0;-0.3) 0.01
Inflammation
hsCRP (mg/l) 0.1 (−2.2;2.3) 0.96 0.1 (−2.7;2.8) 0.95
TNFα (pg/ml) −0.6 (−1.7;0.6) 0.32 −0.7 (−2.0;0.7) 0.31
Intestinal permeability
Lactulose:mannitol (mmol/mol) −0.07 (−0.023;0.008) 0.35 −0.012 (−0.031;0.008) 0.24
Stress parameter
Diurnal cortisol slope −0.08 (−0.36;0.20) 0.54 −0.10 (−0.44;0.25) 0.24
wakeup-bedtime
Abbreviations: TG triglycerides, HDL-C HDL-cholesterol, TC total cholesterol, LDL-C LDL-cholesterol.
Adjusted differences after the intervention between both diets without and with weight loss added to the model.
aDifference = Palaeolithic-type diet – reference diet (with 95% CI).
bP values between the two intervention groups after the intervention.
cAdjusted difference = Palaeolithic-type diet – reference diet (with 95% CI), percentage weight loss added to the model as fixed effect.
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orie than a Mediterranean-like diet. The composition of a
diet is likely to be an important factor in satiety and body-
weight management. It has been reported that a high pro-
tein content of a diet can increase satiety and weight loss
[40,41]. What aspects of a Palaeolithic-type diet are im-
portant in this sense is yet unclear. Spreadbury et al. [42]
reported that consuming a diet of grain-free whole foods
may stimulate gastrointestinal microbiota more consistent
with our evolutionary background. All of these factors
might explain the apparent favourable effects of the mod-
ern “Palaeolithic” diets on satiety and metabolic health.
Limitations
It can be argued that a two weeks dietary intervention is
too short to realize stable effects. Short term positive effectsare followed by relapse in many dietary interventions. In
our study comparison was made with a single blinded refer-
ence diet, rendering our results specific for the Palaeolithic-
type diet per se. Importantly, after two weeks 89% of the
Palaeolithic group and 64% of the reference group were still
motivated to continue their dietary regimes. It will conse-
quently be of utmost importance to study the longer term
effects, as Mellberg et al. [19] have reported a significant
decrease in body weight, fat mass and waist circumference
after 6 months, not sustained after 24 months of a
Palaeolithic-type diet compared to a reference diet in obese
postmenopausal women. Specific aspects of the MetS, as
glucose tolerance and probably also other characteristics,
might become phenotypically apparent in the longer run,
while even greater effects might be seen by allowing ad libi-
tum consumption.
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We conclude that two weeks of a Palaeolithic-type diet,
consumed by subjects with characteristics of the MetS,
improved several cardiovascular risk factors compared
to a healthy reference diet. It proved to be considerably
difficult to keep bodyweight stable. Future studies might
take full additional advantage of the greater weight
loss in the Palaeolithic group by applying an ad libitum
study design.
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